The panels employ PCR techniques to test for numerous gastrointestinal bacterial pathogens using one stool swab.

BD (NYSE: BDX) today announced that it completed enrollment in the iliac artery patient cohort in its pivotal AGILITY study.

BD announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY investigational device exemption (IDE) ...

Unlike most early BD deals, where the rights to develop and benefit from overseas markets in the later stage are entirely ...

After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today marked its third ...